Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 8/20 | 0.62 |
| ▸ | AGTR2 | P50052 | 8/20 | 0.62 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7305266 | 0.99 | AGTR1 (0.62) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL683727 | 0.95 | AGTR1 (0.58) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL668336 | 0.94 | AGTR1 (0.57) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL7886344 | 0.94 | AGTR1 (0.53) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL7308359 | 0.94 | AGTR1 (0.53) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL16327937 | 0.93 | AGTR1 (0.61) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL6598015 | 0.92 | AGTR1 (0.54) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL669267 | 0.92 | AGTR1 (0.58) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL329001 | 0.92 | AGTR1 (0.62) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL7887632 | 0.91 | AGTR1 (0.53) | AGTR1AGTR2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2902385-B1 | DEPROTECTION METHOD FOR TETRAZOLE COMPOUND | API CORP (JP) | 2019-01-09 | — | — | EP | disclosed |
| US-9624181-B2 | Method for producing biaryl compound | API CORPORATION (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9527821-B2 | Deprotection method for tetrazole compound | API CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20150239853-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | API CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150239854-A1 | DEPROTECTION METHOD FOR TETRAZOLE COMPOUND | API CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| EP-2902385-A1 | DEPROTECTION METHOD FOR TETRAZOLE COMPOUND | API Corporation (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-2298763-B1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-03-25 | — | — | EP | disclosed |
| EP-2298763-B1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-8735598-B2 | Method for producing 1-biphenylmethylimidazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8735598-B2 | Method for producing 1-biphenylmethylimidazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | KRKA, D.D. NOVO MESTO (SK) | 2008-12-18 | — | — | US | disclosed |
| EP-1931655-A2 | A PROCESS FOR THE PREPARATION OF SARTAN DERIVATIVES AND INTERMEDIATES USEFUL IN SUCH PROCESS | KRKA, D.D., Novo Mesto (SI) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007048361-A1 | A METHOD OF REMOVING THE TRIPHENYLMETHANE PROTECTING GROUP FROM PRECURSORS OF ANTIHYPERTENSIVE DRUGS | ZENTIVA, A.S. (CZ) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007039117-A2 | A PROCESS FOR THE PREPARATION OF SARTAN DERIVATIVES AND INTERMEDIATES USEFUL IN SUCH PROCESS | KRKA, D.D., NOVO, MESTO (SI) | 2007-04-12 | — | — | WO | disclosed |
| US-20070054948-A1 | Purification of olmesartan medoxomil | TEVA PHARMACEUTICALS USA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054948-A1 | Purification of olmesartan medoxomil | TEVA PHARMACEUTICALS USA, INC. | 2007-03-08 | — | — | US | disclosed |
| EP-0503785-B1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-04-25 | — | — | EP | disclosed |
| US-5646171-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-07-08 | — | — | US | disclosed |
| US-5616599-A | HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239853-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | MLX, BMX, BRIX1 | AGTR1 1993/4885AGTR2 954/4885ABCC3 1950/4885 |
| US-20070054948-A1 | Purification of olmesartan medoxomil | AGTR2, AGTR1, REN | AGTR1 2/4885AGTR2 1/4885ABCC3 3660/4885 |
| US-20150239854-A1 | DEPROTECTION METHOD FOR TETRAZOLE COMPOUND | AGTR2, AGTR1, REN | AGTR1 2/4885AGTR2 1/4885ABCC3 2863/4885 |
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | MC5R, NPY5R, ADRA1D | AGTR1 283/4885AGTR2 311/4885ABCC3 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.